Sun Pharmaceutical Industries Limited
SUNPHARMA
Rank in Stocks
#526
Sun Pharmaceutical Industries Limited, a leading generic pharmaceutical... Sun Pharmaceutical Industries Limited, a leading generic pharmaceutical enterprise, is dedicated to the research, development, production, and marketing of both proprietary and unbranded medicinal formulations, alongside active pharmaceutical ingredients (APIs), for distribution across India and international markets. Its extensive product range encompasses treatments for numerous therapeutic fields, including central nervous system disorders, dermatological conditions, cardiovascular diseases, oncology, ophthalmic care, neuropsychiatry, gastrointestinal issues, infectious diseases, diabetes management, pain relief, nutritional supplements, respiratory ailments, gynaecology, urology, orthopaedics, nephrology, and dental health, among others. The company additionally provides APIs crucial for the creation of anti-cancer drugs, peptides, steroids, sex hormones, and controlled substances. Its generic medications are available in various forms, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquid preparations. Furthermore, Sun Pharma develops specialized medications and a variety of over-the-counter health products. The company was established in 1983 and operates from its headquarters in Mumbai, India.
Share Price
$19.24
Last synced: 2026-10-19
Market Cap
$46.15B
Change (1 day)
-0.97%
Change (1 year)
0.11%
Country
IN
Trade Sun Pharmaceutical Industries Limited (SUNPHARMA)
Category
Healthcare
Revenue for Sun Pharmaceutical Industries Limited (SUNPHARMA)
Revenue in Jun 2026 TTM: $6.61B
According to Sun Pharmaceutical Industries Limited latest financial reports the company's current revenue (TTM) is $6.61B. In 2024 the company made a revenue of $5.82B an increase over the revenue in the year 2023 that was $5.34B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Sun Pharmaceutical Industries Limited from 2004 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $6.61B | 7.55% |
| 2025 | $6.15B | 5.70% |
| 2024 | $5.82B | 8.91% |
| 2023 | $5.34B | 4.87% |
| 2022 | $5.09B | 11.28% |
| 2021 | $4.58B | 4.98% |
| 2020 | $4.36B | 4.14% |
| 2019 | $4.19B | 3.17% |
| 2018 | $4.06B | -15.97% |
| 2017 | $4.83B | 13.79% |
| 2016 | $4.24B | -3.35% |
| 2015 | $4.39B | 63.63% |
| 2014 | $2.68B | 29.00% |
| 2013 | $2.08B | 31.80% |
| 2012 | $1.58B | 22.91% |
| 2011 | $1.28B | 47.70% |
| 2010 | $869.23M | 3.29% |
| 2009 | $841.54M | 0.33% |
| 2008 | $838.79M | 70.54% |
| 2007 | $491.84M | 33.83% |
| 2006 | $367.50M | 33.92% |
| 2005 | $274.42M | 20.98% |
| 2004 | $226.82M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| - | - |
CN
|
